Healthcare · Intelligence
Federal Drug Pricing Policy: How Washington Regulates What Medicare Pays
Federal drug pricing policy is the set of statutes and agency rules — most significantly the Inflation Reduction Act of 2022 — that give Medicare limited authority to negotiate prices on selected high-spend drugs and require manufacturers to pay rebates when prices rise faster than inflation. It does not set prices across the private insurance market.
The basic structure
Prescription drug prices in the United States are set through a mix of private negotiation between manufacturers, insurers, and pharmacy benefit managers, and a smaller but growing set of direct federal levers. For an executive tracking this space, the most important distinction is between what the federal government can require and what it can only influence. Federal drug pricing policy today operates mainly through Medicare, the federal health insurance program for people 65 and older and some younger people with disabilities — not through the commercial insurance market, which remains governed by private negotiation.
The Inflation Reduction Act's three main levers
- Medicare Drug Price Negotiation Program: CMS selects a limited number of high-spend Medicare Part D and Part B drugs each year and negotiates a 'maximum fair price' directly with the manufacturer, phased in starting with prices effective in 2026.
- Inflation rebates: manufacturers must pay a rebate to Medicare when they raise the price of a covered drug faster than the rate of inflation, which applies more broadly than the negotiation program.
- Part D redesign: changes to the Medicare Part D benefit structure, including an annual out-of-pocket cap for beneficiaries, which reshapes incentives across the supply chain even though it isn't a price control in the traditional sense.
Why this matters for advocacy strategy
Because the negotiation program is administered through an annual CMS process with defined selection criteria, comment periods, and litigation exposure, organizations engaging on drug pricing are typically working two tracks at once: the legislative track (potential statutory changes to the program itself) and the regulatory/administrative track (how CMS implements existing law year to year). Federal lobbying activity in this space tends to cluster around both tracks, which is why we track it as its own category in the Federal Lobbying Intelligence Index rather than folding it into general healthcare lobbying.
Sources
- [1] Inflation Reduction Act of 2022, Pub. L. 117-169 — Congress.gov
- [2] Medicare Drug Price Negotiation Program — Centers for Medicare & Medicaid Services